Sanofi SA
SAN
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Sanofi SA News & Analysis
retirement
The top shares of Australia’s best performing super funds
And our equity analysts’ outlook for the stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,416.60 | 20.80 | -0.22% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,824.44 | 156.41 | 0.61% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,986.12 | 1,379.41 | 2.10% |
| NZX 50 Index | 13,853.42 | 29.29 | 0.21% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,227.20 | 22.40 | -0.24% |
| SSE Composite Index | 3,962.44 | 22.40 | 0.57% |